David Nanus, M.D., discusses evolving therapeutic strategies in the neoadjuvant and adjuvant setting for patients with RCC at the 2017 Interdisciplinary Prostate Cancer Congress. Read more
Weill Cornell Medicine and NewYork-Presbyterian have been named to the nonprofit Stand Up 2 Cancer’s Colorectal Dream Team to drive new advances in colorectal cancer research and treatment. The interdisciplinary team, funded... Read more
A $12 million award from the Stand Up to Cancer Foundation will help fund trials testing Vitamin C as a therapy for patients with colon, lung and pancreatic cancers. Read more
In the first demonstration of the potential for CAR-T therapy for previously untreatable advanced thyroid cancers, researchers from the Meyer Cancer Center were able to eliminate cancerous cells in cultures and mice. Read more
Women with a healthy body mass index (BMI) may be at risk of developing breast cancer because of enlarged fat cells in their breast tissue that trigger an inflammatory process, according to Andrew Dannenberg, M.D. Read more
A computational tool created by graduate students predicts how people’s livers, hearts and other tissues might respond to different drugs, in order to ID potentially dangerous side effects before the drugs are tested in people. Read more
Ekta Khurana, Ph. D., assistant professor of computational genomics has created a computational tool that can mine terabytes of overlooked genomic data to uncover potentially unknown drivers of cancer. Read more
Ithaca associate Claudia Fischbach-Teschl, Ph.D., has secured more than $1 million in funding from the Human Frontier Science Program (HFSP) to study breast cancer’s effect on the mineralization pathways in bone. Read more
A substantial N.I.H. budget cut would undermine the fiscal stability of universities and medical schools, many of which depend on N.I.H. funding; it would erode America’s leadership in medical research; and it would diminish opportunities to discover new ways to prevent and treat diseases, argues Harold Varmus, M.D. Read more
Patient-derived organoids are allowing researchers and clinicians to take precision medicine to the next level, according to a new paper by Mark Rubin and Lewis Cantley. Read more